Medicure Inc V.MPH

Alternate Symbol(s): MCUJF

Healthcare Biotechnology

Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

TSXV:MPH - Post by User

Medicure Inc

Bullboard Posts

Comment by apainteron May 30, 2015 2:24pm

150 Views

Post# 23781071

RE:RE:RE:Excellent results!!!

Hi All,

An excellent positive article about Medicure by an ex employee of the Co.

https://www.cantechletter.com/2015/03/medicure-is-persevering-on-the-prairies/

However, only this paragraph worries me
How much can AGGRASTAT grow? Sales for the GP IIb/IIIa inhibitor class have been steadily declining over the past decade. Integrillin, the leading GP IIb/IIIa inhibitor, will likely be generic mid-2015, putting price pressure on the class. So AGGRASTAT is not without its ongoing challenges. However, with only about 4% market share and increasing hospital adoption, near-term growth for AGGRASTAT seems like a safe bet.

Any comments or insight on this would be appreciated
Thanks

Bullboard Posts

Junior helium stock to benefit from new legislation in U.S.